Compare iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares S&P GSCI Commodity-Indexed Trust ETF vs Novartis AG — how do they compare? iShares S&P GSCI Commodity-Indexed Trust ETF trades at $30.85, while Novartis AG trades at $152.99 (market cap $287.66B). The key difference: Novartis AG pays a 3.14% dividend while iShares S&P GSCI Commodity-Indexed Trust ETF pays none. Which is the better fit depends on your goals.
| GSG | NVS | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $34.77 | $168.62 |
52-Week Low | $22.06 | $113.50 |
Market Cap | — | $287.66B |
Enterprise Value | — | $327.68B |
Dividend Yield | — | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NVS trades at $152.51, up 1.43% today, with a bearish technical signal despite strong profitability metrics including a 75.38% gross margin and 35.21% ROE. Recent earnings show mixed results, missing Q1 2026 estimates but beating Q4 2025. The company is actively expanding its oncology pipeline through acquisitions like Myricx Bio for up to $1.5 billion (Reuters, 2026-07-06).
The outlook is balanced; robust cash flow and high margins support growth, but rising debt-to-asset ratios and cautious analyst consensus (68% hold) indicate near-term headwinds. Key risks include execution of pipeline developments and competitive pressures in pharmaceuticals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
